San Diego, California–(Newsfile Corp. – October 7, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today a collaboration with Paul Hutson, PharmD and Christopher Nicholas, PhD to support clinical pharmacology studies for the Company’s…


Previous articlePsygen Announces use of Psilocybin in Human Trial and Provides Update on IP Portfolio
Next articlePTSF80 – Decriminalization in Seattle, San Pedro, and The Dark Web